Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939770 · OUTCOME

Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma · Source last updated 2020-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 8 years

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Analysis population: Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)

Groups in this outcome

Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID

Part B: Patients with ALK+ relapsed/refractory neuroblastoma

Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID

Part C: Patients with ALK+ relapsed/refractory ALCL

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID14
Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID10

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID1Not reportedNot reportedNot reportedNot reported
Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      10
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
groups
  1. description
    Part B: Patients with ALK+ relapsed/refractory neuroblastoma
    id
    OG000
    title
    Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID
  2. description
    Part C: Patients with ALK+ relapsed/refractory ALCL
    id
    OG001
    title
    Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID
param Type
COUNT_OF_PARTICIPANTS
population Description
Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)
reporting Status
POSTED
time Frame
Up to 8 years
title
Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice